94% of participants maintained seroresponse five years after a single vaccinationComparable antibody persistence observed in older (65+) and younger adultsData further reinforce IXCHIQ®'s differentiated profile with
Data from infant immunogenicity and safety trial, and controlled human infection model (CHIM) trial, demonstrate favorable safety profile with encouraging immunogenicity and efficacy signals Lyon (France), November 9,
Lyon (France), November 4, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that it will report its nine-month 2026 financial results on Tuesday, November 24, 2026. The Company
Lyon (France), October 14, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that its senior management will present and participate in meetings with institutional investors at
Lyon (France), October 07, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that, following a further benefit-risk assessment of IXCHIQ® for travelers by the United Kingdom’s (UK)
Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN, PARIS:VLA) today announced that the
Submission based on favorable efficacy and safety results from Phase 3 VALOR trial
Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN, PARIS:VLA) today announced that the European Medicines Agency (EMA) has
Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and
Lyon (France), July 22, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that it will report its first half 2026 financial results on Thursday, August 13, 2026. The Company will
Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that shareholders approved all
Lyon (France), June 4, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company ("the Company"), today announced the availability of documentation for its Annual General Meeting ("the Meeting") to be held
Lyon (France), May 28, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences
Total product sales of €30.5 million Cash position of €105.3 million as of end March 2026, excluding proceeds from successful reserved offering completed in April 20261Program launched in April to further reduce
Lyon (France), May 05, 2026 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026. The Company will
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ:VALN). Such investors are advised to contact
